Cohort-based association study of germline genetic variants with acute and chronic health complications of childhood cancer and its treatment: Genetic risks for childhood cancer complications Switzerland (GECCOS) study protocol

Supplementary Table 1: In- and exclusion criteria for the established sub-projects on pulmonary complications, hearing loss, and second primary neoplasms.

Tradiation of any dose potentially including the lungs: a. Total body irradiation; b. Total lung irradiation; c. Radiation to the chest including the lungs; d. Spinal irradiation; e. Radiation to the upper abdomen or the neck. Chemotherapies with known and suspected lung-toxic agents: a. Bleomycin; b. Busulfan; c. Nitrosoureas (Carmustine, Lomustine); d. High-dose Methotrexate. Chemotherapies with known and suspected lung-toxic agents: A. Bleomycin; b. Busulfan; c. Nitrosoureas (Carmustine, Lomustine); d. High-dose Methotrexate. Chemotherapies with known and suspected lung-toxic agents: A. Bleomycin; b. Busulfan; c. Nitrosoureas (Carmustine, Lomustine); d. High-dose Methotrexate. Chemotherapies with known and suspected lung-toxic agents: A. Bleomycin; b. Busulfan; c. Nitrosoureas (Carmustine, Lomustine); d. High-dose Methotrexate. Chemotherapies with known and suspected lung-toxic agents: A. Bleomycin; b. Busulfan; c. Nitrosoureas (Carmustine, Lomustine); d. High-dose Methotrexate. Chemotherapies with known and suspected lung-toxic agents: A. Bleomycin; b. Busulfan; c. Nitrosoureas (Carmustine, Lomustine); d. High-dose Methotrexate.	Outcome of	Inclusion criteria	Exclusion criteria
including the lungs: a. Total body irradiation; b. Total lung irradiation; c. Radiation to the chest including the lungs; d. Spinal irradiation; e. Radiation to the upper abdomen or the neck. 2) Chemotherapies with known and suspected lung-toxic agents: a. Bleomycin; b. Busulfan; c. Nitrosoureas (Carmustine, Lomustine); d. High-dose Methotrexate. Hearing loss 1) Irradiation to the head of 30 Gy or more biopsies) biopsies) 1) Pre-existing hearing loss before start of the cancer treatment	interest		
a. Total body irradiation; b. Total lung irradiation; c. Radiation to the chest including the lungs; d. Spinal irradiation; e. Radiation to the upper abdomen or the neck. 2) Chemotherapies with known and suspected lung-toxic agents: a. Bleomycin; b. Busulfan; c. Nitrosoureas (Carmustine, Lomustine); d. High-dose Methotrexate. Hearing loss 1) Irradiation to the head of 30 Gy or more 1) Pre-existing hearing loss before start of the cancer treatment	Pulmonary	1) Irradiation of any dose potentially	Surgery to the lungs (except
b. Total lung irradiation; c. Radiation to the chest including the lungs; d. Spinal irradiation; e. Radiation to the upper abdomen or the neck. 2) Chemotherapies with known and suspected lung-toxic agents: a. Bleomycin; b. Busulfan; c. Nitrosoureas (Carmustine, Lomustine); d. High-dose Methotrexate. Hearing loss 1) Irradiation to the head of 30 Gy or more 1) Pre-existing hearing loss before start of the cancer treatment	dysfunction		biopsies)
c. Radiation to the chest including the lungs; d. Spinal irradiation; e. Radiation to the upper abdomen or the neck. 2) Chemotherapies with known and suspected lung-toxic agents: a. Bleomycin; b. Busulfan; c. Nitrosoureas (Carmustine, Lomustine); d. High-dose Methotrexate. Hearing loss 1) Irradiation to the head of 30 Gy or more 1) Pre-existing hearing loss before start of the cancer treatment		a. Total body irradiation;	
lungs; d. Spinal irradiation; e. Radiation to the upper abdomen or the neck. 2) Chemotherapies with known and suspected lung-toxic agents: a. Bleomycin; b. Busulfan; c. Nitrosoureas (Carmustine, Lomustine); d. High-dose Methotrexate. Hearing loss 1) Irradiation to the head of 30 Gy or more 1) Pre-existing hearing loss before start of the cancer treatment		b. Total lung irradiation;	
d. Spinal irradiation; e. Radiation to the upper abdomen or the neck. 2) Chemotherapies with known and suspected lung-toxic agents: a. Bleomycin; b. Busulfan; c. Nitrosoureas (Carmustine, Lomustine); d. High-dose Methotrexate. Hearing loss 1) Irradiation to the head of 30 Gy or more 1) Pre-existing hearing loss before start of the cancer treatment		c. Radiation to the chest including the	
e. Radiation to the upper abdomen or the neck. 2) Chemotherapies with known and suspected lung-toxic agents: a. Bleomycin; b. Busulfan; c. Nitrosoureas (Carmustine, Lomustine); d. High-dose Methotrexate. Hearing loss 1) Irradiation to the head of 30 Gy or more 1) Pre-existing hearing loss before start of the cancer treatment		lungs;	
neck. 2) Chemotherapies with known and suspected lung-toxic agents: a. Bleomycin; b. Busulfan; c. Nitrosoureas (Carmustine, Lomustine); d. High-dose Methotrexate. Hearing loss 1) Irradiation to the head of 30 Gy or more 1) Pre-existing hearing loss before start of the cancer treatment		d. Spinal irradiation;	
2) Chemotherapies with known and suspected lung-toxic agents: a. Bleomycin; b. Busulfan; c. Nitrosoureas (Carmustine, Lomustine); d. High-dose Methotrexate. Hearing loss 1) Irradiation to the head of 30 Gy or more 1) Pre-existing hearing loss before start of the cancer treatment		e. Radiation to the upper abdomen or the	
suspected lung-toxic agents: a. Bleomycin; b. Busulfan; c. Nitrosoureas (Carmustine, Lomustine); d. High-dose Methotrexate. Hearing loss 1) Irradiation to the head of 30 Gy or more 1) Pre-existing hearing loss before start of the cancer treatment		neck.	
suspected lung-toxic agents: a. Bleomycin; b. Busulfan; c. Nitrosoureas (Carmustine, Lomustine); d. High-dose Methotrexate. Hearing loss 1) Irradiation to the head of 30 Gy or more 1) Pre-existing hearing loss before start of the cancer treatment		2) Chemotherapies with known and	
b. Busulfan; c. Nitrosoureas (Carmustine, Lomustine); d. High-dose Methotrexate. Hearing loss 1) Irradiation to the head of 30 Gy or more 1) Pre-existing hearing loss before start of the cancer treatment		suspected lung-toxic agents:	
c. Nitrosoureas (Carmustine, Lomustine); d. High-dose Methotrexate. Hearing loss 1) Irradiation to the head of 30 Gy or more before start of the cancer treatment		a. Bleomycin;	
Lomustine); d. High-dose Methotrexate. Hearing loss 1) Irradiation to the head of 30 Gy or more 1) Pre-existing hearing loss before start of the cancer treatment		b. Busulfan;	
d. High-dose Methotrexate. Hearing loss 1) Irradiation to the head of 30 Gy or more 1) Pre-existing hearing loss before start of the cancer treatment		c. Nitrosoureas (Carmustine,	
Hearing loss 1) Irradiation to the head of 30 Gy or more 1) Pre-existing hearing loss before start of the cancer treatment		Lomustine);	
more before start of the cancer treatment		d. High-dose Methotrexate.	
treatment	Hearing loss	1) Irradiation to the head of 30 Gy or	1) Pre-existing hearing loss
		more	before start of the cancer
2) Changath arousing with two arous			treatment
2) Cnemotnerapies with known		2) Chemotherapies with known	
hearing-toxic agents: 2) Surgery involving the ear		hearing-toxic agents:	2) Surgery involving the ear
a. Cisplatin; which were associated with		a. Cisplatin;	which were associated with
b. Carboplatin; hearing loss.		b. Carboplatin;	hearing loss.
c. Oxaliplatin		c. Oxaliplatin	
3) Survivors of leukemia, CNS tumors,		3) Survivors of leukemia, CNS tumors,	
neuroblastoma, soft tissue sarcomas, and			
germ cell tumors who were not exposed			
to established ototoxic treatments (as			
defined above) but who are suspected to		`	
be at risk for hearing loss due to		, 1	
potential additional risk such as other		-	
drugs like aminoglycosides or loop		1 -	
diuretics.			

Second	1) Cases with second primary	Identified from medical
primary	neoplasms	records, follow-up reports to
neoplasms		the SCCR, linkage with
	2) Matched control design:	cantonal cancer registries,
	matched by demographic, primary	death records, and
	cancer diagnosis, and treatment factors,	questionnaire information (as
	age at primary diagnosis, follow-up	defined by IARC)[1]
	time, year of primary neoplasm	72 2
	treatment, and exposure to relevant	
	treatments (e.g. chest radiation, or	
	alkylating agents), where appropriate.	
	3) Case-cohort design: Random	
	selection of a subcohort from all	
	childhood cancer survivors and retrieval	
	of the same information as needed for	
	the cases.	

Supplementary Table 2: Clinical information collected for the three established sub-projects on pulmonary dysfunction, hearing loss and second primary neoplasms.

Pulmonary	Spirometry	Forced vital capacity (FVC),
dysfunction		Forced expiratory volume in
		1 second (FEV1), Peak
		expiratory flow (PEF),
		Maximum expiratory flow
		(MEF (25-75)
	Body plethysmography	Total lung capacity (TLC),
		Vital Capacity (VC),
		Functional residual capacity
		(FRC), Residual volume
		(RV)
	Carbon monoxide diffusion capacity	mmol/min/kPa corrected for
	corrected for hemoglobin (DLCO)	hemoglobin if available
	Personal history and symptoms	Self-reported questionnaire
		information on recurrent
		pneumonias, chronic cough,
		and risk factors for lung
		problems (smoking, etc.)

Hearing loss	Audiometry	Bilateral pure tone
		audiometry with air and bone
		conduction spanning 125 Hz
		to 8,000 Hz (where available
		up to 16,000 Hz)
	Video otoscopy	Assessment of the tympanic
		membrane (where available)
	Personal history and symptoms	Self-reported questionnaire
		information on hearing loss,
		tinnitus, hearing aid use, and
		exposure to noise
Second		
primary	Age at diagnosis	Years
neoplasms	Date of diagnosis	Month/ year
	Type of diagnosis	ICCC3 code; ICDO3
		morphology, topography,
		behavior code
	Laterality	Left/ right/ bilateral/ medial/
		not applicable
	Relapse date	Month/ year
	Relapse type	Local/ distant/ systemic/
		other
	Relapse location	Organ and morphology
	Treatment information	Cumulative doses of
		individual antineoplastic
		agents and radiotherapy

Legend: IARC, International Agency for Research on Cancer; SCCR, Swiss Childhood Cancer Registry; Hz, Hertz

References

1. Working Group Report. International rules for multiple primary cancers (ICD-0 third edition): European Journal of Cancer Prevention. 2005;14:307–8.